Acura Pharmaceuticals Inc. (NASDAQ:ACUR) shares were up 8.6% on Tuesday . The stock traded as high as $2.03 and last traded at $2.01, with a volume of 64,287 shares. The stock had previously closed at $1.85.

Several research analysts have weighed in on ACUR shares. FBR & Co reissued a “buy” rating on shares of Acura Pharmaceuticals in a report on Friday, June 10th. Roth Capital reaffirmed a “buy” rating and issued a $6.00 price target on shares of Acura Pharmaceuticals in a report on Wednesday, April 13th. Finally, Zacks Investment Research lowered shares of Acura Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, April 29th.

The firm’s market capitalization is $23.78 million. The company’s 50-day moving average is $2.10 and its 200-day moving average is $2.34.

Acura Pharmaceuticals (NASDAQ:ACUR) last issued its earnings results on Monday, May 2nd. The specialty pharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.02. On average, equities research analysts anticipate that Acura Pharmaceuticals Inc. will post ($1.01) earnings per share for the current fiscal year.

Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.